Anant Shah

Anant Shah started their professional career as a Research Technician at the University of Chicago Hospitals in July 2012. They then joined the University of Virginia School of Medicine as a Graduate Student in August 2013. During their time there, Anant focused on studying the role of TGIFs in colorectal cancers and secured grants to fund their research. They discovered that TGIFs promote colorectal cancers by repressing genes involved in aceytl-CoA metabolism and published a paper documenting their findings.

In September 2019, Anant became a Postdoctoral Researcher at Beth Israel Deaconess Medical Center. They conducted research on a promising new immune checkpoint pathway involving the receptor HHLA2 and its potential as a druggable pathway for clear cell renal cell carcinoma (ccRCC). Anant gained experience with orthotopic mouse models, dosing mice with drugs and antibodies, and immune-oncological mouse models. They also worked on a project exploring the molecular basis for the anti-inflammatory protein A20's positive regulation of glucose and lipid metabolism using animal and cell-based models. They gained experience with adenovirus and AAV-mediated gene therapy, diabetic mouse models, lentiviral infection, and mutagenesis.

Most recently, Anant joined Entrada Therapeutics in June 2022 as a Scientist I, where their specific role and responsibilities are not provided.

Anant Shah completed their Bachelor's degree in Biological Sciences at Northwestern University from 2008 to 2012. Later, they pursued further education at the University of Virginia School of Medicine. From 2013 to 2015, Anant obtained a Master of Science (MS) degree in Biochemistry, Biophysics, and Molecular Biology. They continued their studies at the same institution and completed a Doctor of Philosophy (PhD) degree in Biochemistry and Molecular Biology from 2013 to 2018.